

Patient Name: Sample Patient
Referring Physician: John Doe, M.D.
Patient ID: 20000000-1

Client #: 12345

City Hospital
1 Main Street
Anywhere, USA

DOB: 11/22/1985 **Lab ID:**
SSN: ***-**-**** **Hospital ID:**

Pregnancy information used in risk calculations:

Gestational Age: US 11/18/2015 **NT:** 1.2 mm **CRL:** 52 mm
Sonographer: Jane Doe

of Fetuses: 1 **Race:** Hispanic **DS Hx:** No **NTD Hx:** No
Age At Term: 30.5 **Weight:** 140 Lbs. **IDDM:** No

First Trimester Serum

Specimen #: 22739666-1
Date Collected: 11/18/2015
Date Received: 11/19/2015
GA: 11.7 weeks

Second Trimester Serum

Specimen #: 22820124-1
Date Collected: 01/04/2016
Date Received: 01/05/2016
GA: 18.4 weeks

Results:	NT	PAPP-A	AFP	HCG	UE3	Inhibin
	1.02 MoM	1.63 MoM	0.91 MoM	1.08 MoM	0.97 MoM	0.91 MoM
MoM Cutoff:			<2.50			

INTERPRETATION : Screen Negative

	Screening Risk	Age Related Risk	Risk Cutoff
Down Syndrome	1:10,000	1:720	1:270
Trisomy 18	1:10,000	1:2,800	1:100
ONTD	1:6,000	N/A	1:145

IntegratedScreen will detect approximately 92% of Down Syndrome and approximately 90% of Trisomy 18 fetuses. This test does not reliably detect other chromosomal abnormalities.

A negative NTD screen rules out approximately 80% of open neural tube defects. This screen does not detect closed or very small neural tube defects.

Maternal screening has some level of inherent false negative and false positive results and is not a substitute for diagnostic testing. It remains standard of care to offer prenatal diagnosis to women age 35 or older at term.

Please check the patient information used in this risk assessment and call with any corrections.

Integrated Genetics is a business unit of Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.

Under the direction of:

Philip R. Wyatt M.D., Ph.D

Date: 01/06/2016

Page 1 of 1